{"id":448848,"date":"2021-03-02T16:08:22","date_gmt":"2021-03-02T21:08:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=448848"},"modified":"2021-03-02T16:08:22","modified_gmt":"2021-03-02T21:08:22","slug":"yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","title":{"rendered":"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, March  02, 2021  (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference.<\/p>\n<p>The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning March 9, starting at 7:00am EST.<\/p>\n<p>\n        <strong>About Yumanity Therapeutics<\/strong><br \/>\n        <br \/>Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity\u2019s pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\u2019s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\u2019s disease.\u00a0\u00a0 For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IeWecCCXw7QGTjFcE1h6H13ZANA3cX4W0vuKMf8wEigW5vIwHGboYW2MpIUdeaPdDG0AZNxiaT-QTR13aufpNg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.yumanity.com<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Burns McClellan, Inc.<br \/>John Grimaldi<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iVYXptbETO2ZIAccx11tNJpy5YzWhcssB-HiAc4DAFQokWoQBld5-95R5x0SCIA94i-llfLMgmXOnnzkzcPTo0uOy4axCnngfOcqGDqAcU8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jgrimaldi@burnsmc.com<\/a><br \/>(212) 213-0006<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Burns McClellan, Inc.<br \/>Ryo Imai \/ Robert Flamm, Ph.D.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R-MnPPnryUtPecII8Eg_8w6vMP27pplwAFDrtbW5cFt3orEXS_aIlkJ6LvdRcJYx15-bPl0bIQ3FBECNxzjqBg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rimai@burnsmc.com<\/a> \/ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bNZwjP7unwotLXmrNI1zLKI5ER6VhFBOqu5lZFEnlC4f0BRMFJ3vQ5dogXUlMz_9xe-1L3u1-dUCuMghy1iuRNey6-FYwlh8OdzeL4D5-Rk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rflamm@burnsmc.com<\/a><br \/>(212) 213-0006<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/be433a78-4fa8-433f-8ec6-ee49eb808ca2\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, March 02, 2021 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning March 9, starting at 7:00am EST. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-448848","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, March 02, 2021 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning March 9, starting at 7:00am EST. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. &hellip; Continue reading &quot;Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-02T21:08:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference\",\"datePublished\":\"2021-03-02T21:08:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\"},\"wordCount\":231,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\",\"name\":\"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=\",\"datePublished\":\"2021-03-02T21:08:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","og_description":"BOSTON, March 02, 2021 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning March 9, starting at 7:00am EST. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. &hellip; Continue reading \"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-02T21:08:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference","datePublished":"2021-03-02T21:08:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/"},"wordCount":231,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","name":"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=","datePublished":"2021-03-02T21:08:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjE0OSM0MDQyMjA2IzIyMDAzMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/448848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=448848"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/448848\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=448848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=448848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=448848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}